secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2026-05-27T20:30:22+00:00
Accession:  0001628280-26-038499
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam elects Benjamin F. Cravatt to board; shareholders re-elect directors and approve say-on-pay
--------------------------------------------------------------------------------

- Benjamin F. Cravatt, Ph.D. elected to Board effective June 1, 2026, filling newly created eleventh seat; term expiring 2028 annual meeting.
- Dr. Cravatt receives $75,000 annual cash retainer and initial stock option valued at $600,000 vesting over three years.
- At May 20, 2026 annual meeting, shareholders re-elected Class I directors Arbuckle, Greenstreet, and Sigal with over 95% votes for each.
- Say-on-pay approved with 111.8M for vs 8.6M against; PwC ratified as auditor with 119.8M votes for.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/0001628280-26-038499-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/alny-20260520.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-038499

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer